About

Established in 2007, Stratos Genomics Inc. is a spin-off of Seattle-based Stratos Group LLC. The company is composed of an accomplished team of scientists, engineers, advisors and directors.

Management Team

Mark Kokoris, CEO
Mark Kokoris
President, CEO and Board Member
20+ years of experience working on the cutting edge of biotechnology. Mr. Kokoris’s passion is to conceive and develop innovative and transforming technologies. He co-founded Stratos Genomics in 2007 in order to pursue a vision of creating a next generation DNA sequencing technology that would enable broader use in healthcare. In pursuit of this goal, Mr. Kokoris co-invented the SBX™ technology that same year. In 2003, he founded the biotechnology consulting firm BioCaptus, LLC where his experience in the fields of high throughput genomics, molecular diagnostics, protein engineering, and microfluidics was utilized by clients to develop a broad range of technologies and applications.
Bob McRuer
Bob McRuer, Ph.D.
CTO and Board Member
25+ years of instrumentation design, optics/electro optics, and project management experience. Dr. McRuer’s product development experience includes detection and measurement systems for life science and medical products, fluorescence microscopy, SPR, image analysis, thermal control, microfluidics, electrowetting, laser scanning and liquid crystals. He has expertise in plastic optics manufacturing, optomechanical design, diffractive/micro optics, illumination, microdisplays, thin film development, and metrology.
John Tabone, VP Chemistry
John Tabone, Ph.D.
Vice President, Chemistry
25+ years in a startup environment developing innovative technologies in the areas of nucleoside chemistry, molecular diagnostics, genomic measurement, and high throughput automation of oligonucleotide and gene synthesis.  Dr. Tabone led design and implementation of a highly automated scalable gene manufacturing platform for a leading US gene synthesis company, Blue Heron Biotech. While at Microprobe he managed the late stage development and manufacture of a 510k-approved DNA diagnostic. He was an inventor of the CMST SNP mass spectrometry-based measurement technology and led its development through to an early commercial stage.
Melud Nabavi, VP Molecular Engineering
Melud Nabavi
Vice President, Molecular Engineering
20+ years of experience in biotechnology developing innovative genomics technologies.   Melud joined Stratos Genomics in 2010 leading the Molecular Engineering effort.  In 2003, he was a founding member of BioCaptus developing technologies and applications for clients in high throughput genomics, microfluidics and molecular diagnostics.  Melud continued as consultant for Merck/Rosetta Inpharmatics developing the Molecular Profiling Portfolio Management System, evaluating and implementing molecular profiling technologies.  Before Biocaptus, Melud held several positions in high-throughput genomics technologies as a Manager and R&D Associate at Qiagen Genomics, Cereon Genomics (Monsanto)

Additional Board Members

Lee Huntsman
Lee Huntsman, Ph.D.
Chairman- Stratos Genomics Inc, President Emeritus- University of Washington
In July 2005, Lee Huntsman was selected by Washington Governor Christine Gregoire as the executive director of the Life Sciences Discovery Fund Authority, a public-private partnership intended to give life sciences research in the state a major boost.
Harold Kawaguchi
Chairman- Stratos Group, LLC
Mr. Kawaguchi has over 30 years experience in working with emerging growth companies. He was an officer of Physio-Control Corporation, where he helped lead the company through its growth years until its merger with Eli Lilly Corporation. He was also a board member of Pacer Corporation, Wall Data, Active Voice, and Redhook Brewery, all NASDAQ-listed companies.
Stephen L. Rose, CPA, CMA
Director- Fisk Ventures, LLC
Stephen L. Rose serves as Managing Director of Fisk Ventures, LLC, the venture investment company for H. Fisk Johnson, Ph.D., the Chairman and CEO of S.C. Johnson and Son Inc. In this capacity, Mr. Rose serves on the boards of several early-stage, technology-based companies, and has over 17 years of experience in venture investing. Formerly, over a 10-year period with S.C. Johnson, both in the US and in Canada, he held several positions, including strategic planning, new business, and new product development, along with financial and business management. Steve has an Honors Bachelor of Commerce from McMaster University and is also a Certified Management Accountant (CMA).
Heiner Dreismann, Ph.D.
Heiner Dreismann, Ph.D.
Retired CEO- Roche Molecular Systems
From 2000 to 2006, Dr. Dreismann was President and CEO of Roche Molecular Systems (RMS), a division of F. Hoffmann-La Roche Ltd. and the company that pioneered molecular diagnostics in the clinical arena. During his tenure as CEO, RMS annual sales doubled to US$ 1.2 billion and the portfolio of tests and hardware sales were greatly expanded. Dr. Dreismann led the introduction of PCR-based tests in Europe as early as 1992 and witnessed firsthand the industry growth over the last two decades. Prior to being appointed CEO, Dr.

Scientific Advisory Board

Todd M. Smith Ph.D.
Dr. Smith co-founded Geospiza, Inc. and served in several roles (CEO, CTO) until its acquisition by PerkinElmer (PKI) in 2011 where he continued to develop genomics strategies and products until 2013.  His technical and market knowledge is broad with depth in the areas of bioinformatics, genomics, systems biology, and software systems with a clinical and diagnostic focus. Dr. Smith provides consulting services through Digital World Biology to help organizations develop genetic analysis strategies and technical implementation plans.  Prior to Geospiza, Dr. Smith was postdoctoral scientist in Dr.
Tim Hunkapiller, Ph.D.
President- Discovery Biosciences Corporation
Dr. Hunkapiller received his Ph.D. from the California Institute of Technology in Molecular Biology, and most recently has held a Research Assistant Professor appointment in the Department of Molecular Biotechnology at the University of Washington.  Dr. Hunkapiller's research focus has included molecular immunology, evolution, computational genetics, comparative genomics and he is an expert on the genetics, genomic organization and functional diversity of the immune system. He has also been involved in bioinformatics, algorithm and database development, and experimental process optimization, for 20 years. While at Caltech, Dr.
Eugene Kolker, Ph.D.
Eugene Kolker, Ph.D.
Chief Data Officer- Seattle Children’s Hospital
Eugene Kolker is Chief Data (Analytics) Officer at Seattle Children’s -- Hospital, Foundation, and Research Institute. Kolker has over 25 years of experience in multi-disciplinary data analysis, predictive analytics, and modeling and over 15 years of experience in management, business, and community development. At Seattle Children’s, Kolker heads the CDOAnalytics team, which focuses on leveraging large and complex data to improve outcomes and safety, reduce costs, broaden access, and drive innovation (cdoanalytics.org). In addition to the hospital work, he is also director of Bioinformatics & High-throughput Analysis Laboratory (kolkerlab.org) at the Research Institute.
Patrick Stayton, Ph.D.
Professor of Bioengineering- University of Washington
Patrick Stayton currently serves as the Washington Research Foundation Professor in the Department of Bioengineering at the University of Washington.  He received his B.S. in Biology (summa cum laude, Chemistry minor) from Illinois State University in 1984, his Ph.D. in Biochemistry from the University of Illinois in 1989, and was a Postdoctoral Research Associate at the Beckman Institute for Advanced Science and Technology, also at the University of Illinois. 
Buddy D. Ratner, Ph.D.
Professor of Bioengineering- University of Washington
Dr. Ratner is one of the founding fathers of modern bioengineering and most recently was elected a Fellow of the American Association For the Advancement of Science (AAAS). Dr. Ratner is the Michael L. and Myrna Darland Endowed Chair in Technology Commercialization, Professor of Bioengineering and Professor of Chemical Engineering at the University of Washington. He received his Ph.D. (1972) in polymer chemistry from the Polytechnic Institute of Brooklyn.
Andre Marziali, Ph.D.
Andre Marziali, Ph.D.
Founder, President and Chief Science Officer- Boreal Genomics Associate, Professor of Physics and Astronomy- University of British Columbia
Dr. Andre Marziali is an Associate Professor of Physics and Astronomy, Director of Engineering Physics and an Associate with the Michael Smith Laboratories at the University of British Columbia. He received his BSc in Engineering Physics from the University of British Columbia in 1989. He did his PhD (1994) with H.A. Schwettman in Physics at Stanford University, specializing in superconducting particle accelerators and free electron lasers. From 1994 to 1998, he was the lead engineer of Technology Development at the Stanford Sequencing and Technology Centre, working with Ron Davis of the Biochemistry Department.
Bob Franza, MD
Affiliate Professor of Bioengineering- University of Washington
Dr. Franza is a scientist, physician and professor with decades of experience in quantitative systems biology, information technology, and entrepreneurial research and development endeavors.  He received his MD from Georgetown University in 1979. After his residency in Internal Medicine at Dartmouth – Mary Hitchcock Medical Center he joined the scientific staff of Cold Spring Harbor Laboratory.
Lawrence A. Loeb, MD, Ph.D.
Professor of Pathology and Biochemistry- University of Washington
Research in Dr. Loeb’s laboratory is focused on the molecular basis of mutagenesis.  Their long-term interest is in understanding the fidelity of DNA polymerases in normal human cells and the origin and consequences of random mutations in aging and in human cancers.
Jay Shendure, MD, Ph.D.
Jay Shendure, MD, Ph.D.
Assistant Professor of Genome Sciences- University of Washington
At the University of Washington, Dr. Shendure’s lab is investigating how high-throughput technologies can have a transformative impact on biomedical research. They are broadly interested in developing new experimental methods and computational tools for the parallelized interrogation of biological systems. Ongoing projects in the laboratory make extensive use of new platforms for array-based, programmable DNA synthesis and massively parallelized, short-read DNA sequencing.